Skip to main content
OpenTrials
Completed

NCT Number: NCT03463369

A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

The purpose of this study is to evaluate the safety, tolerability, and reactogenicity of escalating doses of JNJ-64300535 delivered via electroporation-mediated intramuscular injection in nucleos(t)ide analogs (NA)-treated chronic hepatitis B (CHB) participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis B, Chronic Blood-Borne Infections Chronic Disease Communicable Diseases DNA Virus Infections Digestive System Diseases Disease Attributes Hepadnaviridae Infections Hepatitis Hepatitis B Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Virus Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

ZiekenhuisNetwerk Antwerpen (ZNA) - Stuivenberg, Antwerp, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has chronic hepatitis B virus envelope antigen (HBeAg) negative hepatitis B virus (HBV) infection documented by a positive hepatitis B virus surface antigen (HBsAg) test and/or detectable HBV deoxyribonucleic acid (DNA) at least 6 months prior to the screening visit
  • Is on a stable treatment with one of the approved oral nucleos(t)ide analogs (NA) polymerase inhibitors tenofovir alafenamide, tenofovir disoproxil fumarate, or entecavir for greater than or equal to (>=)12 months prior to screening. A history of switching between the above treatments is acceptable as long as it was not triggered by virologic failure
  • Must demonstrate HBV DNA levels less than (<)60 international unit/milliliter (IU/mL) on 2 occasions separated by greater than (>)6 months (of which one can be the screening assessment).
  • Has HBsAg levels at screening between 100 IU/mL and 10,000 IU/mL
  • Has normal alanine aminotransferase (ALT) levels for at least 6 months prior to baseline with no documented measurement exceeding 1.25 times upper limit of normal [ULN]). Minimal requirement is documentation of two ALT results within the year prior to baseline of which one can be the screening assessment.

Exclusion criteria

  • Presence of advanced hepatic fibrosis or cirrhosis in 1 of the assessments below done less than or equal to (<=)6 month prior to baseline: a. Metavir score 3 or 4 in a liver biopsy OR b. Fibroscan result of >9 kilopascal (kPa) OR c. Acoustic Radiation Force Impulse (ARFI) result of >=1.55 meter/second (m/s)
  • Clinical signs or history of liver cirrhosis or hepatic decompensation:
  • Metavir score 4 in a historical biopsy OR
  • ascites, esophageal varices, or hepatic encephalopathy OR
  • documentation of one of the following laboratory abnormality within 12 months of screening:

i. direct (conjugated) bilirubin >1.2 times upper limit of normal (ULN) OR ii. prothrombin time (PT) >1.2 times ULN OR iii. serum albumin <3.5 gram per deciliter (g/dL)

  • Positive serology test at screening for any of the following:
  • anti-hepatitis B surface (ant-HBs) antibodies
  • HBeAg
  • anti-human immunodeficiency virus (HIV)-1 or anti-HIV-2 antibodies
  • anti-hepatitis A virus (HAV) immunoglobulin M (IgM) antibodies
  • anti-hepatitis C virus (ant-HCV) antibodies
  • anti-hepatitis D virus (anti-HDV) antibodies
  • Participants with any evidence of liver disease of non-HBV etiology. This includes but is not limited to hepatitis A, C, or D virus infections (as above), drug- or alcohol-related liver disease, autoimmune hepatitis, hemochromatosis, Wilson's disease, α-1 antitrypsin deficiency, primary biliary cirrhosis, primary sclerosing cholangitis, non-alcoholic steatohepatitis or any other non-HBV liver disease considered clinically significant by the investigator
  • Has a history of persistent or recurrent hyperbilirubinemia unless explained by known Gilbert's Disease
  • History of blood disorders (bleeding problems or a blood clot, thalassemia major or sickle cell anemia).
  • History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions.

Treatment and study plan

JNJ-64300535

Biological

Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.

Placebo

Biological

Participants will receive 1 mL (0.9 percent [%] sodium chloride [NaCl]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.

Nucleos(t)ide Analogs (NA)

Drug

Participants will receive NA as a standard of care treatment.

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) by Severity and Relationship to Study Treatment and Dose Level

    Time frame: Up to Week 16

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of AEs will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events as follows: Mild = Grade 1, Moderate = Grade 2, Severe = Grade 3, Potentially life-threatening = Grade 4.

  2. Number of Participants With Laboratory Abnormalities

    Time frame: Up to Week 16

    Number of participants with laboratory abnormalities related to hematology, serum chemistry, coagulation, liver function tests and urinalysis will be reported. Laboratory abnormalities will be graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events as follows: Mild = Grade 1, Moderate = Grade 2, Severe = Grade 3, Potentially life-threatening = Grade 4.

  3. Number of Participants With Clinically Significant Changes in Vital Signs

    Time frame: Up to Week 16

    Number of participants with clinically significant changes in the vital signs including blood pressure, pulse/heart rate, and body temperature will be reported.

  4. Number of Participants With Clinically Significant Changes in Physical Examination (Palpation of Lymph Nodes, Height, Body Weight, and Skin Examination) Findings

    Time frame: Up to Week 16

    Number of participants with clinically significant changes in physical examination parameters will be reported. Full physical examination (including palpation of lymph nodes, height, body weight, and skin examination) and symptom-directed physical examination will be performed.

  5. Number of Participants With Acute Injection Site Reactions on Day 1

    Time frame: From 0 to 2 hours post-vaccination on Day 1

    Participants will be assessed for the acute injection site reactions. Acute reactions means the reactions which occur within 0 to 2 hours post-vaccination. Acute reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.

  6. Number of Participants With Acute Injection Site Reactions at Week 4

    Time frame: From 0 to 2 hours post-vaccination at Week 4

    Participants will be assessed for the acute injection site reactions. Acute reactions means the reactions which occur within 0 to 2 hours post-vaccination. Acute reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.

  7. Number of Participants With Acute Injection Site Reactions at Week 12

    Time frame: From 0 to 2 hours post-vaccination at Week 12

    Participants will be assessed for the acute injection site reactions. Acute reactions means the reactions which occur within 0 to 2 hours post-vaccination. Acute reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.

  8. Number of Participants With Injection Site Reactions After Vaccination on Day 1

    Time frame: Up to 7 days post-vaccination on Day 1

    Participants will be assessed for the Reactogenicity. Reactogenicity means injection site reactions which occur after 7 days post- vaccination. Severity of reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.

  9. Number of Participants With Injection Site Reactions After Vaccination on Week 4

    Time frame: Up to 7 days post-vaccination on Week 4

    Participants will be assessed for the Reactogenicity. Reactogenicity means injection site reactions which occur after 7 days post-vaccination. Severity of reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.

  10. Number of Participants With Injection Site Reactions After Vaccination on Week 12

    Time frame: Up to 7 days post-vaccination on Week 12

    Participants will be assessed for the Reactogenicity. Reactogenicity means injection site reactions which occur after 7 days post- vaccination. Severity of reactions will be graded as follows: Grade 0 = Normal, Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Potentially Life Threatening.

Secondary outcomes

  1. Percentage of Participants With a Positive Hepatitis B Virus (HBV) Specific T Cells Response

    Time frame: Day 1, Week 2, 6, 14, 24, 48, and 60

    Percentage of participants with a positive HBV-specific T cells response, assessed by interferon (IFN)-gamma ELISpot assay will be reported.

  2. Time to Detection of HBV Specific T-Cell Responses

    Time frame: Day 1 up to Week 60

    Time to HBV Specific T-Cell response is defined as the time interval between Day 1 (vaccination) to the date of first evidence of positive HBV Specific T-Cell response.

  3. Percentage of CD4+ and CD8+ T-Cell Responses

    Time frame: Day 1, Week 2, 6, 14, 24, 48, and 60

    The activation of CD4+ and CD8+ T-cell subsets and their cytokine expression patterns (expressing at least 1 interleukin [IL]-2, tumor necrosis factor-alpha [TNF-α] or IFN-γ specific to any antigen) will be determined by Intracellular Cytokine Staining (ICS).

  4. Hepatitis B Antigen-Specific Cellular Immune Response

    Time frame: Day 1, Week 2, 6, 14, 24, 48, and 60

    Magnitude of Hepatitis B antigen-specific cellular immune responses will be assessed by ICS.

  5. Number of TriGrid Delivery System (TDS)-Intramuscular (IM) v2.0 Device Fault Conditions by Type

    Time frame: Day 1, Week 4 and 12

    Number of TDS-IM v2.0 device fault conditions by type will be observed. User reported fault conditions will be documented to enable assessment of the device reliability. Device functions to be assessed include electrode/needle deployment, study treatment administration, and electroporation application.

Sponsors and collaborators

Lead sponsor

Janssen Sciences Ireland UC

Industry

Registry information

Official study title

A First-In-Human, Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(T)Ide Therapy and Virologically Suppressed

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Mar 13, 2018
Registry last updated
Apr 14, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.